A Cross-Sectional Time Course of COVID-19 Related Worry, Perceived Stress, and General Anxiety in the Context of Post-Traumatic Stress Disorder-like Symptomatology

Roger J. Mullins 1,†, Timothy J. Meeker 1,*,‡, Paige M. Vinch 1, Ingrid K. Tulloch 2, Mark I. Saffer 1, Jui-Hong Chien 1, O. Joseph Bienvenu 3 and Frederick A. Lenz 1

1 Department of Neurosurgery, Johns Hopkins University, Baltimore, MD 21287, USA; rmullin3@jh.edu (R.J.M.); pvinch1@jhu.edu (P.M.V.); msaffer3@jhmi.edu (M.I.S.); jchien7@jhmi.edu (J.-H.C.); flenz1@jhmi.edu (F.A.L.)
2 Department of Psychology, Morgan State University, Baltimore, MD 21251, USA; ingrid.tulloch@morgan.edu
3 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD 21287, USA; obienve1@jhmi.edu
* Correspondence: tmeeker3@jhmi.edu; Tel.: +1-(410)-955-2257
† These authors contributed equally to this work.

Abstract: The COVID-19 pandemic within the United States of America resulted in over 800,000 deaths as of February 2022 and has been addressed by social distancing or stay-at-home measures. Collective prolonged multimodal trauma on this scale is likely to elicit symptomatology in the general population consistent with post-traumatic stress disorder (PTSD), somatization, anxiety, and stress. The psychological component of this response contributes substantially to the burden of this disease worldwide. This cross-sectional study examines the relationship between COVID-19-related concern, anxiety, and perceived stress on PTSD-like symptomatology over the course of the COVID-19 pandemic. Participants were recruited via social media within the United States of America between 8th May 2020 and 11th August 2021 to complete an internet questionnaire including mood, personality, and COVID-19-specific scales. General anxiety and PTSD-like symptomatology were above the screening cutoffs for most respondents. These measures increased in severity over the pandemic, with the change point of our Concern scale preceding that of the other significant measures. Measures of COVID-19-related concern, generalized anxiety, and PTSD-like symptomatology were strongly correlated with each other. Anxiety, perceived stress, and PTSD-like symptomatology are strongly interrelated, increase with pandemic length, and are linked to reported levels of concern over COVID-19. These observations may aid future research and policy as the pandemic continues.

Keywords: COVID-19; post-traumatic stress disorder; survey; questionnaire; somatization

1. Introduction

Since the first case of disease from the novel coronavirus, SARS-CoV-2, causing COVID-19, was diagnosed in the United States (US) on 20 January 2020, numerous states and municipalities have instituted various levels of social distancing and stay-at-home measures [1]. As of 1 February 2022, the US CDC reported that there were more than 75 million confirmed positive cases of infection with the novel coronavirus and more than 884,853 deaths. Given the widespread impact of these events, the known ability of collective mass multimodal trauma to induce psychiatric disorders such as generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and comorbid functional pain syndromes, it is likely that there will be a surge in mental health and general health complaints following the COVID-19 pandemic comparable to that of the 9/11 terrorist attacks [2–7]. Participants reporting high levels of general anxiety, perceived stress, and somatization, the propensity to report internal body sensations in the terms of possible illness, are at a greater risk for GAD, PTSD, and comorbid functional pain syndromes [6,8–12].
While several studies have examined the effects of collective mass multimodal trauma on PTSD and GAD, the contribution of somatization has rarely been investigated [6,13]. Somatization should be a particularly important factor in a pandemic environment with social distancing and stay-at-home orders, where self-report and perception of relevant symptoms may be heightened. Additionally, during the continuing COVID-19 pandemic, widespread adoption of vaccination in the United States and the slow return of society to normal provided a natural temporal experiment to investigate the temporal evolution of interrelations of perceived stress symptoms, general anxiety, and traumatic-stress-like symptoms.

During the global COVID-19 pandemic, numerous studies have reported strong relationships between measurement scales for anxiety, perceived stress, and post-traumatic symptomatology. Strong correlations between anxiety and perceived stress were revealed by many surveys using the GAD-7 and PSS scales [14–23]. Anxiety and PTSD-like symptomatology have also shown consistent positive correlations during the pandemic, as measured by the GAD-7 and IES scales [24–26]. Similarly, post-traumatic symptomatology relates to perceived stress measured by the PSS and IES scales [27], while somatization has been shown to correlate strongly with anxiety, perceived stress, and post-traumatic symptomatology [28] during the pandemic.

Given the highly intercorrelated nature of the symptoms implied by these measures, one response has been to narrow the focus toward the common feature of concern, fear, or worry specifically related to the COVID-19 pandemic. This self-reported factor holds a strong relation to the prior measures and may have substantial explanatory power [29–31]. Some researchers even present the possibility that pandemic-related concern may represent its own type of trauma [32].

The objective of this study was to determine the temporal relationships among general anxiety, perceived stress, COVID-19-related concern, somatization, and post-traumatic stress symptomatology. We hypothesized that the persistent stress of the COVID-19 pandemic would increase perceived stress, followed by generalized anxiety, leading to the expression of post-traumatic stress symptomatology. Our first research question pertained to how general measures of anxiety and perceived stress would relate to more specific measures of somatization, post-traumatic stress symptomatology, and COVID-19-related concern. We predicted a positive relationship between these measures. Our second research question was how these measures would change over the observed course of the COVID-19 pandemic, predicting a general increase over time with peaks reflective of change points when and if the trend diverted. Our third research question involved how COVID-19-related concern would be related to measures of behavior that could lead to SARS-CoV-2 exposure, with our prediction being an inverse relationship.

2. Materials and Methods

2.1. Survey Participation

Subjects answered questions from standardized psychological questionnaires (see Table 1) as well as a novel COVID-19-specific questionnaire developed specifically for this study. Recruitment took place as advertisements on social media sites such as Twitter, Facebook, Reddit, and institutionally affiliated research websites. Potential participants used a web link to the survey and completed several psychological questionnaires. Because of the nature of the study, the Johns Hopkins School of Medicine Institutional Review Board waived informed consent. Each participant was assigned a participant number to uniquely identify their data and keep protected health information separate from their responses to COVID-19-specific and more general health and psychological surveys. This survey was implemented with a Qualtrics XM account and required approximately 60 to 120 min to complete. Participants were allowed to save their data and continue the survey later to complete it. The first participant completed the survey on 8 May 2020, and it was closed to new responses on 11 August 2021.
Table 1. Psychometric properties of standard scales.

| Name       | Items | Item Range | Scores                                      | Score Range | Cronbach’s α |
|------------|-------|------------|---------------------------------------------|-------------|--------------|
| GAD-7      | 7     | 0–3        | Anxiety                                     | 0–21        | 0.92         |
| ASI        | 16    | 0–4        | Anxiety sensitivity                         | 0–64        | 0.91         |
| PHQ-9      | 9     | 0–3        | Depression                                  | 0–27        | 0.90         |
| SF-36      | 36    | 0–100      | Physical functioning                        | 0–100       | 0.93         |
|            |       |            | Physical health                             | 0–100       | 0.88         |
|            |       |            | Emotional problems                          | 0–100       | 0.86         |
|            |       |            | Energy/fatigue                              | 0–100       | 0.83         |
|            |       |            | Emotional well-being                        | 0–100       | 0.85         |
|            |       |            | Social functioning                          | 0–100       | 0.86         |
|            |       |            | Pain                                        | 0–100       | 0.85         |
|            |       |            | general health                              | 0–100       | 0.83         |
| Big 5      | 100   | 1–5        | Surgency                                    | 10–100      | 0.92         |
|            |       |            | Agreeableness                               | 10–100      | 0.90         |
|            |       |            | Conscientiousness                           | 10–100      | 0.91         |
|            |       |            | Stability                                    | 10–100      | 0.90         |
|            |       |            | Intellectual                                 | 10–100      | 0.89         |
| PSQ        | 17    | 0–10       | Total pain sensitivity                       | 0–140       | 0.93         |
|            |       |            | Moderate pain sensitivity                    | 0–70        | 0.91         |
|            |       |            | Minor pain sensitivity                       | 0–70        | 0.87         |
| PSS-14     | 14    | 0–4        | Perceived stress total                      | 0–56        | 0.89         |
| IES-6      | 6     | 0–4        | PTSD-like symptomatology                     | 0–4 (mean)  | 0.86         |
|            |       |            | Intrusion                                   | 0–4 (mean)  | 0.84         |
|            |       |            | Avoidance                                   | 0–4 (mean)  | 0.71         |
|            |       |            | Hyperarousal                                | 0–4 (mean)  | 0.76         |
| PSQI       | 7     | 0–3        | Global sleep quality                        | 0–21        | 0.74         |
| PILL       | 54    | 0–4        | Somatization total                          | 0–216       | 0.94         |
| SSS-8      | 8     | 0–4        | Somatization total                          | 0–32        | 0.80         |
| SSD-12     | 12    | 0–4        | Somatization total                          | 0–48        | 0.94         |
|            |       |            | Cognitive                                   | 0–16        | 0.74         |
|            |       |            | Affective                                   | 0–16        | 0.86         |
|            |       |            | Behavioral                                  | 0–16        | 0.91         |

2.2. Measures

In addition to the independent COVID-19-specific questions (see Supplementary Data), the online survey evaluated anxiety (GAD-7 [33], Anxiety Sensitivity Inventory [34]), PTSD-like symptomatology (Impact of Events Scale-6 [35,36]), somatization (Pennebaker’s Inventory of Limbic Languidness [37]), Somatic Symptom Scale-8 [38], and Somatic Symptom Disorder–B criteria scale [39], depression (PHQ-9 [40]), neuroticism (as inverse of stability on the Big Five Factor Scale [41]), perceived stress (Perceived Stress Scale-14 [42]), health-related quality of life (SF-36 [43]), pain sensitivity (Pain Sensitivity Questionnaire [44]), and sleep quality (Pittsburgh Sleep Quality Inventory [45]). See Table 1 for the psychometric properties of these measures. The start of the pandemic in January 2020 was indicated as the event for the IES-6 scale.

2.3. Data Analysis

All analyses were performed in R (version 4.1.0, R Core Team 2021, Vienna, Austria). Questionnaire responses were downloaded and collated using the R QualtRics package (version 3.1.5). A custom R script calculated the derived scores and subscores for each of
the assessment scales, based on the scoring methods described in their original sources. Data were excluded if the respondent spent less than two minutes on the survey or did not report a valid US zip code. Sporadic missing data were accounted for within each questionnaire using PCA imputation (R package missMDA, version 1.18), ranging from 0 to 10.4%. Entirely empty rows of data within a questionnaire were not imputed and instead reflected in the number of participants, with such nonresponses ranging from 15.9% to 53.4% of the data as the survey progressed. Simple multiple-choice arithmetic and general knowledge questions were interspersed within the survey to assess attention, such as “4 + 5 =” and “which of the following things is alive.” Responses for these questions were consistently correct throughout the survey and no data were excluded on that basis.

To condense the COVID-19-specific questions into composite scores, we performed a factor analysis of the COVID-19-related questions in R package FactoMiner (version 2.4) using the PCA and FactoInvestigate functions. This PCA analysis was used to evaluate assumptions that specific groups of these questions would reflect issues of concern or worry, levels of estimated exposure, and physical symptoms related to COVID-19.

Age, sex, education, and race were assessed for potential demographic effects on the measures included in the questionnaire. This analysis used a series of linear regressions with age, race, sex, or education as the independent variable and each separate measure as the dependent variable. Higher age was associated with lower PSS-14 totals. Higher age was also associated with higher SF-36 role limitations due to emotional problems, COVID-19-specific questionnaire Concern scale scores, SF-36 energy/fatigue, and Big 5 Stability. Higher education was associated with lower PHQ-9 and PSS totals. There were no significant differences in the questionnaire measures for sex or race after Benjamini–Hochberg (BH) correction for multiple comparisons, but sex was retained as a covariate due to the notably large proportion of female respondents (77%). See Supplementary Table S2 for statistics related to the selection of covariates.

Scale-to-scale comparisons used a partial correlation between each score, with age, sex, and years of education as covariates. The Benjamini–Hochberg procedure was used to adjust resultant p-values for multiple comparisons. Tests of the difference between two correlated correlations were performed using the r.test function of the R psych package (version 2.1.9).

We used a general linear model to assess cross-sectional changes in questionnaire responses over the course of the pandemic. The independent variable was time, expressed as the number of days since the start of the study. Scores for the scales used were the dependent variable, with age, sex, and years of education as covariates. The Benjamini–Hochberg procedure was used to adjust the resultant p-values for multiple comparisons. To assess the point in the cross-sectional time series in which the trend “breaks” or changes direction, we also used change point analysis (R changepoint package version 2.2.2) using the At Most One Change (AMOC) algorithm.

3. Results
3.1. Demographics

General characteristics of the respondents are shown in Table 2, with expanded information available in Supplementary Table S1. Geographic location of respondents is in Figure 1. The sample tended toward respondents who are white (72%), female (77%), possess some college education (29%), or earn income under 40,000 USD per year (39%). All reported valid zip codes located within the United States of America.
Table 2. General characteristics of respondents.

| Demographic                  | N (%) or Mean ± SD |
|------------------------------|--------------------|
| Total participants           | 408                |
| Age in years (range 17–85)   | 34.1 ± 13.11       |
| Sex                          |                    |
| Female                       | 314 (77%)          |
| Intersex                     | 1 (0.2%)           |
| Male                         | 91 (22.3%)         |
| Race                         |                    |
| White                        | 293 (71.8%)        |
| Native Hawaiian or Other Pacific Islander | 0 (0%)         |
| Black or African             | 39 (9.6%)          |
| Asian American               | 28 (6.9%)          |
| American Indian or Alaska Native | 2 (0.5%)    |
| Other                        | 33 (8.1%)          |
| Refuse                       | 4 (1%)             |
| Do Not Know                  | 7 (1.7%)           |

Figure 1. Geographic location of respondents. Figure created in R mapview package; area of circles represents the number of respondents in that US zip code.

3.2. COVID-19-Specific Questionnaire

According to the responses to the COVID-19-specific questions in the survey, most respondents stayed home to avoid infection (73%) and started isolation in March 2020 (59.3%). The majority wore a mask when going outside of their home (58.6%) with the most popular choice being a cloth mask (44.1%). A plurality was either a little bit (26.5%) or moderately worried (20.8%) about contracting COVID-19 within the next month. Response breakdowns for other individual COVID-19-specific questions are shown in Supplementary Table S3.

Cross-Sectional Analysis of Individual COVID-19-Specific Questions

Some behaviors and attitudes measured by the COVID-19-specific questions changed over the survey period. Over time, there were significant cross-sectional increases in
the response values toward the questions “How many people do you live with in your residence?” (F (4, 338) = 15.86, p = 1.56 × 10^{−10}) and “Are you able to perform most of your job functions working remotely from home?” (F (4, 331) = 8.73, p = 0.00002). There were cross-sectional decreases in response values toward the questions “Do you believe that you have a higher risk for serious illness from the novel coronavirus or COVID-19?” (F (4, 322) = 10.32, p = 1.62 × 10^{−6}), “Considering any chronic diseases you may have, how concerned are you that you may contract the novel coronavirus or COVID-19 in the next month?” (F (4, 322) = 6.31, p = 0.0014), “How often are you exercising per week?” (F (4, 335) = 5.08, p = 0.01) and “How much news or other COVID-19-related content have you watched each day in the past week?” (F (4, 322) = 4.94, p = 0.013). Change point analysis did not reveal any discernible breaks in the trends over the survey period.

3.3. Factor Analysis for Subscale Generation

To draw out composite measures of COVID-19-related concern, exposure, and symptomatology, principal component (PCA) factor analysis was performed on a subset of the 24 COVID-19-specific questions that yielded ordinal or continuous outcomes. This revealed two primary dimensions explaining 29.9% of the total inertia of the dataset, with dimension 1 explaining 16.5% and dimension 2 explaining 13.4%. The questions were divided into three scales: Concerns, Exposure, and Symptoms. The PCA factor dimensions and valence (+/−) were used to guide and assess the scale membership of each question. Questions comprising the Concern and Symptoms scales fell largely within the same factor but were retained as separate scales based on prior intent. Four questions were excluded as their factor cosine was less than 0.10 in the highest dimension, leaving a total of 20 questions with explanatory power. The remaining individual responses were then divided by their maximum possible value, reverse scored if their dimension factor was negative, and averaged. For ease of interpretation, we multiplied each fractional average scale by 100 to fit a 1–100 scale. See Table 3 for details. Cronbach alpha scores for the three scales were Concern = 0.79, Exposure = 0.75, and Symptoms = 0.29. Only the more reliable Concern and Exposure scales were carried forward into the following analyses.

Table 3. Factor analysis for COVID-specific subscales.

| Q# | Dim.1 | Dim.2 | Scale | Question (Paraphrased) |
|----|-------|-------|-------|------------------------|
| 61 | −0.36 | 0.16  | Concern | Wearing a mask when going outside. |
| 81 | 0.75  | 0.15  | Concern | Worry about contracting COVID-19 in the next month. |
| 82 | 0.75  | −0.12 | Concern | Concern about leaving residence due to COVID-19. |
| 84 | 0.44  | −0.23 | Concern | Frequency of watching news about COVID-19. |
| 85 | 0.74  | −0.05 | Concern | Concern over chronic disease-related COVID-19 vulnerability. |
| 86 | 0.59  | −0.02 | Concern | Perceived risk for serious COVID-19-related illness. |
| 54 | −0.32 | 0.56  | Exposure | Stay home to avoid infection. |
| 58 | −0.24 | 0.66  | Exposure | People within 6 feet. |
| 59 | −0.19 | 0.62  | Exposure | People in physical contact. |
| 60 | −0.29 | 0.67  | Exposure | Left place of residence last week. |
| 63 | 0.06  | −0.66 | Exposure | Employed as Essential Worker. |
| 64 | 0.13  | 0.54  | Exposure | Able to perform job remotely. |
| 80 | −0.32 | −0.52 | Exposure | Contact with COVID-19-infected person in past week. |
| 70 | 0.27  | 0.44  | Symptoms | Taking temperature in the past week. |
| 71 | 0.48  | 0.19  | Symptoms | Cough in the past week. |
| 72 | 0.52  | 0.22  | Symptoms | Breathing trouble in the past week. |
| 74 | 0.37  | 0.14  | Symptoms | Chills in the past week. |
| 75 | 0.34  | 0.18  | Symptoms | Lost sense of smell in the past month. |
| 78 | 0.38  | 0.15  | Symptoms | Consulted Doctor about COVID-19 in past month. |
| 79 | −0.36 | −0.33 | Symptoms | Contracted COVID-19 in the past month. |

Note: Q# is question number, Dim. is the dimension number (1 or 2).
3.4. Threshold for Anxiety, Depression, and PTSD-like Symptomatology

The key standard assessment scales for anxiety and PTSD-like symptomatology include guidelines or cutoff thresholds considered symptomatic for those conditions. The average respondent exceeded these thresholds midway through the pandemic period assessed by the survey. A score of 1.75 on the IES-6 total indicates substantial PTSD-like symptoms [36]. The mean IES-6 total was 1.8 ± 1.0 (95% CI: 1.74–1.96), and this threshold was met or exceeded by the majority (55.8%) of respondents by September 2020. The GAD-7 indicates symptoms of anxiety with a cutoff of 10 [33]. The mean GAD-7 total was 10.4 ± 6.4 (95% CI: 9.69–11.10), with the clinical threshold exceeded by 56.1% of the respondents by September 2020. Timeline plots with cutoffs for the primary measures of interest based on our aims are shown in Figure 2. Descriptive statistics for all assessment scales are found in Table 4, and a complete set of timeline plots for all measures is available as Supplementary Figure S1.

![Figure 2](image-url)
Table 4. Descriptive statistics for questionnaire measures.

| Measure                                      | N     | Mean ± SD       | 95% CI        | MAR  |
|----------------------------------------------|-------|-----------------|---------------|------|
| COVID-19-Specific Questionnaire:             |       |                 |               |      |
| Concern                                     | 347   | 51.37 ± 15.84   | 49.7–53.04    | 4.1% |
| Exposure                                    | 347   | 41.91 ± 14.46   | 40.38–43.43   | 1.2% |
| Symptoms                                    | 347   | 34.56 ± 6.75    | 33.84–35.27   | 2.1% |
| Anxiety:                                    |       |                 |               |      |
| GAD-7 total                                  | 319   | 10.39 ± 6.4     | 9.69–11.11    | 0.6% |
| ASI total                                    | 213   | 19.88 ± 13.69   | 18.03–21.73   | 0.4% |
| Personality/Neuroticism:                    |       |                 |               |      |
| Big 5 Surgency                              | 213   | 100.17 ± 28.4   | 96.34–104.01  | 1.6% |
| Big 5 Agreeableness                         | 213   | 132.11 ± 22.81  | 129.03–135.19 | 2.0% |
| Big 5 Conscientiousness                     | 213   | 123.28 ± 24.21  | 120.01–126.55 | 2.0% |
| Big 5 Emotional Stability                   | 213   | 90.75 ± 26.09   | 87.22–94.27   | 1.7% |
| Big 5 Intellect                             | 213   | 133.56 ± 22.8   | 130.48–136.64 | 1.9% |
| Somatization:                                |       |                 |               |      |
| PILL total                                   | 213   | 57.44 ± 32.68   | 53.03–61.86   | 0.9% |
| SSS-8 total                                  | 319   | 10.66 ± 6.47    | 9.95–11.37    | 0.9% |
| SSD-12 total                                 | 319   | 16.39 ± 11.09   | 15.17–17.61   | 0.1% |
| SSD-12 cognition                             | 319   | 5.13 ± 3.51     | 4.75–5.52     | 0.2% |
| SSD-12 affective                             | 319   | 6.16 ± 4.08     | 5.71–6.61     | 0.0% |
| SSD-12 behavioral                            | 319   | 5.31 ± 4.45     | 4.82–5.8      | 0.1% |
| Depression:                                  |       |                 |               |      |
| PHQ-9 total                                  | 313   | 12.57 ± 7.13    | 11.77–13.36   | 1.0% |
| PTSD-like Symptomatology:                   |       |                 |               |      |
| IES-6 total                                  | 330   | 1.85 ± 1        | 1.74–1.96     | 0.1% |
| IES-6 Intrusion                              | 330   | 1.82 ± 1.12     | 1.7–1.94      | 0.2% |
| IES-6 Avoidance                             | 330   | 1.71 ± 1.13     | 1.58–1.83     | 0.0% |
| IES-6 Hyperarousal                          | 330   | 2.02 ± 1.26     | 1.88–2.15     | 0.2% |
| Perceived Stress:                            |       |                 |               |      |
| PSS-14 total                                 | 214   | 31.21 ± 9.93    | 29.87–32.55   | 0.3% |
| General Health:                              |       |                 |               |      |
| SF-36 Physical Functioning                   | 214   | 84.25 ± 22.55   | 81.21–87.29   | 1.7% |
| SF-36 Physical Role Limitations              | 214   | 62.97 ± 41.16   | 57.42–68.51   | 2.1% |
| SF-36 Emotional Role Limitations             | 214   | 31.91 ± 41.17   | 26.36–37.46   | 2.5% |
| SF-36 Energy/Fatigue                         | 214   | 31.64 ± 21.84   | 28.69–34.58   | 1.8% |
| SF-36 Emotional Well-being                   | 214   | 45.2 ± 23.53    | 42.03–48.37   | 1.6% |
| SF-36 Social Functioning                     | 214   | 54.06 ± 33.04   | 49.61–58.51   | 2.3% |
| SF-36 Pain                                   | 214   | 71.41 ± 24.11   | 68.16–74.66   | 1.2% |
| SF-36 General Health                         | 214   | 55.93 ± 22.8    | 52.86–59.01   | 0.7% |
| Pain Sensitivity:                             |       |                 |               |      |
| PSQ minimal                                  | 212   | 19.04 ± 10.54   | 17.62–20.47   | 0.4% |
| PSQ moderate                                 | 212   | 31.35 ± 12.28   | 29.69–33.02   | 0.5% |
| PSQ total                                    | 212   | 50.4 ± 21.5     | 47.49–53.31   | 0.4% |
| Sleep Quality:                               |       |                 |               |      |
| PSQI Global score                            | 197   | 9.23 ± 4.4      | 8.61–9.85     | 2.6% |

Note: CI is confidence interval (lower–upper), MAR is missing-at-random.

3.4.1. Association between Generalized Anxiety and PTSD-like Symptomatology

We predicted that general anxiety and perceived stress would positively correlate with somatization, post-traumatic stress symptomatology, and COVID-19-related concern. Partial correlation analysis showed strong positive associations (Figure 3A) between scores for COVID-19-related Concern, generalized anxiety (GAD-7), perceived stress (PSS-14), and PTSD-like symptomatology (IES-6). The entire battery of measures also showed consistent associations among most scales (Figure 3B).
3.4.2. Cross-Sectional Trajectory of Standard and COVID-19-Specific Measures

To assess changes in attitudes and symptomatology over time, the COVID-19 survey included a series of standard assessments for anxiety, somatization, pain sensitivity, stress, and aspects of personality. There were cross-sectional increases in the scores for PSS-14 total, SSS-8 total, GAD-7 total, SSDB total, PHQ-9 total, SSDB affective subscore, SSD-12 behavioral subscore, SSD-12 cognitive subscore, IES-6 Avoidance, ASI total, and PILL total. There were cross-sectional decreases over time in the scores for SF-36 energy/fatigue, SF-36 social functioning, Big 5 stability, SF-36 role limitations due to emotional problems, and SF-36 role limitations due to physical health. Statistics for these significant scales are available in Table 5, and a complete list of statistics including nonsignificant results is in Supplementary Table S5.

Change point analysis revealed trend deflections in November 2020 for the PILL total, March 2021 for the PSS-14 and ASI total, April 2021 for the GAD-7 total, SSD-12 total, and SF-36 physical health subscales, May 2021 for the PHQ-9 total, and June 2021 for the SF-36 energy/fatigue, SF-36 Social Functioning, Big-5 Stability, SF-36 role limitations due to emotional problems, and PILL total.

Next, we focused on the question of whether COVID-19-related concern would be inversely related to measures of behavior that could lead to SARS-CoV-2 exposure. During the course of the COVID-19 pandemic captured in the survey, only the Concern scale showed a significant decrease over time (F(4, 321) = 6.84, p = 0.001). The trends for the Concern and Exposure scales were significantly different from each other via the r test of difference between two correlated correlations (T(1, 312) = −3.32, p = 0.001). Change point analysis revealed downward trend changes in Concern starting in January of 2021 and upward changes in exposure starting June of 2021. Timeline plots of selected scales are
shown in Figure 2, timeline plots for all measures are shown in Supplementary Figure S1, and statistics for each of the standard assessment scales are in Supplementary Table S4.

Table 5. Linear model results for assessment scales during the COVID-19 pandemic.

| Scale                        | df  | F     | p-Value (BH) | Change Point |
|------------------------------|-----|-------|--------------|--------------|
| PSS-14 total                 | 4, 207 | 10.98 | 0.00000 | March 2021   |
| SSS-8 total                  | 4, 311 | 9.36  | 0.0001 | NA           |
| SF-36 energy/fatigue         | 4, 207 | 8.12  | 0.00013 | June 2021    |
| GAD-7 total                  | 4, 311 | 7.72  | 0.00018 | April 2021   |
| SSD-12 behavioral Concern    | 4, 311 | 6.72  | 0.00097 | NA           |
| SF-36 social functioning     | 4, 207 | 6.68  | 0.00097 | June 2021    |
| SSD-12 total                 | 4, 311 | 6.54  | 0.00119 | April 2021   |
| PHQ-9 total                  | 4, 305 | 6.14  | 0.00263 | May 2021     |
| Big 5 stability              | 4, 206 | 6.11  | 0.00243 | June 2021    |
| SSD-12 cognitive             | 4, 311 | 5.99  | 0.00270 | NA           |
| SSD-12 affective             | 4, 311 | 5.87  | 0.00319 | NA           |
| SF-36 emotional role limitations | 4, 207 | 5.67  | 0.00498 | June 2021    |
| IES-6Avoidance               | 4, 321 | 4.84  | 0.01684 | NA           |
| PILL total                   | 4, 206 | 4.52  | 0.02999 | November 2020|
| SF-36 physical role limitations | 4, 207 | 4.50  | 0.02999 | April 2021   |
| ASI total                    | 4, 206 | 4.16  | 0.04965 | March 2021   |

Note: DF is degrees of freedom (numerator, denominator), F is F-value, BH is Benjamini–Hochberg correction for multiple comparisons.

4. Discussion

This study focused on the related factors of anxiety, perceived stress, somatization, PTSD-like symptoms, and COVID-19-related concern during the COVID-19 pandemic in the United States of America. Over the course of the pandemic from 8 May 2020 to 11 August 2021, we found compelling spikes in these measures matching those found in other studies during this time period [29,31,46–51]. In our cross-sectional analysis, many of these symptoms increased over time, adding a sense of urgency to the understanding that the COVID-19 pandemic has had a deleterious effect on worldwide mental health.

As predicted, we found strong positive correlations between the GAD-7, PSS-14, and IES-6 measures—representing anxiety, perceived stress, and PTSD-like symptoms. These interrelated factors also correlated well with a novel measurement of COVID-19-related concern, lending credence to the idea that these factors are related. No directional component could be inferred from this analysis, partly due to the cross-sectional nature of the measures.

Interestingly, COVID-19 Concern scores decreased during the course of the pandemic as self-reported exposure to potential risks increased. This observation is consistent with the widespread notion of attempting to go “back to normal,” especially after vaccines became available. Measures of anxiety, stress, somatization, and PTSD also correlated strongly with Concern scores, providing some hope that this pattern will reverse itself if and when the threat of COVID-19 recedes.

Change point analysis was used to identify points in the timeline where assessment scores broke or deflected. Our prediction was that perceived stress (PSS-14) scores would change first, followed by general anxiety (GAD-7), then post-traumatic stress disorder-like symptomatology (IES-6). This was borne out in the resulting data which showed the PSS-14 peaking on March 2021, GAD-7 peaking on April 2021, and the IES-6 showing no detectable peak by change point analysis (Figure 2). While the visually discernible peak for IES-6
does seem to follow the trend, this scale either may use too few units within the measure to show fine changes or simply had not actually reached a true change point at the time the survey ended. The COVID-19-related Concern score was by far the earliest indicator, showing downward deflection in January 2021. A salient time point for comparison is December 2020, the month at which COVID-19 vaccines became available. This analysis does not imply causality of one event or measure upon another but does yield insight into the duration of pandemic-related symptomatology.

The relationship between somatic and PTSD-like symptoms has long been evident among veterans with PTSD [52–54]. We found strong positive correlations of somatic symptoms and somatization with COVID-19 Concern scores as well as PTSD-like symptoms in the present study. Interestingly, while somatization as measured by the PILL, SS8, and somatic symptoms as measured by the SSD-12 scale all loaded on the same factor during principal component analysis, indicating a redundancy of information, somatization as measured by the PILL showed a significant change in trajectory in November 2020 and reached its highest point during February and March 2021; the SSD-12 scale of somatic symptoms peaked and demonstrated a change in trajectory in April 2021. Future studies are needed to test whether this was a seasonal effect related to allergies or seasonal affective disorder, since many symptoms listed on the PILL are elevated during bouts of seasonal allergies and may be elevated during seasonal affective disorder [37]. Recent studies have found that elevated somatization in PTSD is related to overall lifetime trauma more strongly than combat exposure and that somatic disorder is present in nearly 60 percent of those with probable PTSD compared to 5 percent of those free of PTSD symptoms [55]. Furthermore, patients with complex PTSD, which is more often a result of trauma exposure of varying types and durations, report greater somatization on the PHQ-15 compared to those with simple PTSD [56]. This study found the relationship between PTSD and somatization is probably bidirectional and mutually maintaining, while the maintenance of PTSD and somatization can still be seen more than 20 years after the events which triggered PTSD [56,57]. Finally, our findings of clinically significant levels of somatization in a large proportion of the general population during the COVID-19 pandemic are consistent with previously published studies in the general population and in healthcare professionals [58–61]. These factors, combined with the high burden of PTSD-like symptoms coupled with somatization in our study, suggest this psychological burden may persist for years following the COVID-19 pandemic.

Limitations of this study include the characteristics of the sample and psychometric features of the COVID-19-specific questions. Unavoidably, respondents were drawn from a sample of those with access to the internet and social media. As participation was not compensated, the sample of respondents may also be skewed toward those with the time or disposition to fully complete the survey without tangible reward. The sex of the respondents also skewed heavily toward female respondents. As for the psychometric features of the COVID-19-specific scales, the current version of the COVID-19-specific subscores for concern, exposure, and symptoms is not designed for hand scoring and is reliant on an automated script. Future revisions to this scale will include regularizing the range of the number of responses within questions to ease manual scoring and the removal of exploratory questions that explained little variance in the responses.

5. Conclusions

Using over a year of online survey data during the COVID-19 pandemic, we found that anxiety, perceived stress, and PTSD-like symptomatology are strongly interrelated, increase with pandemic length, and are strongly linked to reported levels of concern over COVID-19. Further, change point analyses showed peaks for concern preceding other measures, as well as showing downward deflections in symptomatology after the availability of vaccinations. Our results strengthen support for the hypothesis that the trajectory of risk factors leading to PTSD-like symptoms begins with enhanced
general distress coupled with concern or worry about the initiating stressful life events. The initial events, which may threaten life or way of life, snowball into pathological distress, generalized anxiety, and PTSD-like symptomatology. Particularly relevant in the case of a public health disaster but clearly relevant in other etiologies of PTSD, somatization and anxiety sensitivity seem associated with individuals experiencing a greater PTSD-like symptom burden [52,53,57,62–64]. Our current study and other cross-sectional results implicate somatization as a risk factor in the development of PTSD. This may help to explain the high comorbidity between chronic pain disorders and PTSD as somatization is risk factor for both disorders [65–68].

As the pandemic is ongoing, the observations from this study will help inform and guide future research and public policy on this overwhelmingly important worldwide phenomenon. Since greater reports of somatization and anxiety sensitivity are associated with development and severity of PTSD-like symptomatology, these individuals should be prioritized for early intervention during and after disasters. Effective modes of intervention may include early psychological first aid, and traditional group and one-on-one cognitive behavioral therapy (CBT) [69,70]. Business managers, education and healthcare professionals, and others in a supervisory role should be educated in the signs of enhanced perceived stress, somatization and psychological first aid. Resources for CBT and mental health care must be destigmatized, and their availability broadened to ensure those susceptible to PTSD have the resources to remain resilient. Training and the application of psychological first aid and referral to mental health resources should be provided as in-depth programs rather than trivial exercises in regulatory satisfaction [70]. This may be especially necessary in educators, as younger participants seem to experience a greater burden of symptoms that are associated with the development of PTSD [30,62,71–78].

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijerph19127178/s1.

Author Contributions: Conceptualization, T.J.M. and F.A.L.; Data curation, R.J.M., P.M.V. and J.-H.C.; Formal analysis, R.J.M.; Funding acquisition, F.A.L.; Methodology, R.J.M., I.K.T., M.I.S., J.-H.C., O.J.B. and F.A.L.; Supervision, F.A.L.; Validation, R.J.M. and P.M.V.; Writing—original draft, R.J.M. and T.J.M.; Writing—review and editing, R.J.M., T.J.M., P.M.V., I.K.T., O.J.B. and F.A.L. All authors have read and agreed to the published version of the manuscript.

Funding: F.A.L. acknowledges funding from the National Institute of Neurological Disorders and Stroke (R01-NS109298); F.A.L and T.J.M. acknowledge funding from the Johns Hopkins Neurosurgery Pain Research Institute; I.K.T. acknowledges funding from the National Institute of General Medical Sciences (U54-MD013376).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Johns Hopkins University (IRB00248005, approved 5/8/2020).

Informed Consent Statement: Informed consent waived by the Institutional Review Board due to the nature of the study.

Data Availability Statement: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Conflicts of Interest: The authors declare no conflict to interest.

References
1. Omer, S.B.; Malani, P.; del Rio, C. The COVID-19 Pandemic in the US: A Clinical Update. JAMA 2020, 323, 1767–1768. [CrossRef] [PubMed]
2. MacGeorge, E.L.; Samter, W.; Feng, B.; Gillihan, S.J.; Graves, A.R. After 9/11: Goal disruption, emotional support, and psychological health in a lower exposure sample. Health Commun. 2007, 21, 11–22. [CrossRef]
3. Li, J.; Alper, H.E.; Gargano, L.M.; Maslow, C.B.; Brackbill, R.M. Re-experiencing 9/11-Related PTSD Symptoms Following Exposure to Hurricane Sandy. Int. J. Emerg. Ment. Health 2018, 20, 1–7. [CrossRef] [PubMed]

4. Cohen, P.; Kasen, S.; Chen, H.; Gordon, K.; Berenson, K.; Brook, J.; White, T. Current affairs and the public psyche: American anxiety in the post 9/11 world. Soc. Psychiatry Psychiatr. Epidemiol. 2006, 41, 251–260. [CrossRef] [PubMed]

5. Updegraff, J.A.; Silver, R.C.; Holman, E.A. Searching for and finding meaning in collective trauma: Results from a national longitudinal study of the 9/11 terrorist attacks. J. Pers. Soc. Psychol. 2008, 95, 709–722. [CrossRef] [PubMed]

6. Letcher-Kelly, L.; Yam, L.; Brohiier, J.A.; Brand, D.L.; Banker, S.V.; Kotov, R.; Bromet, E.; Bucobo, J.C.; Shaw, R.D.; Luft, B.J. Longitudinal study of the impact of psychological distress symptoms on new-onset upper gastrointestinal symptoms in World Trade Center responders. Psychosom. Med. 2014, 76, 686–693. [CrossRef]

7. Jack, K.; Gled, S. The public costs of mental health response: Lessons from the New York City post-9/11 needs assessment. J. Urban Health 2002, 79, 332–339. [CrossRef] [PubMed]

8. Fillingim, R.B.; Ohrbach, R.; Greenspan, J.D.; Knott, C.; Dubner, R.; Bair, E.; Baraian, C.; Slade, G.D.; Maixner, W. Potential psychosocial risk factors for chronic TMD: Descriptive data and empirically identified domains from the OPPERA case-control study. J. Pain 2011, 12, T46–T60. [CrossRef]

9. Slade, G.D.; Ohrbach, R.; Greenspan, J.D.; Fillingim, R.B.; Bair, E.; Sanders, A.E.; Dubner, R.; Diatchenko, L.; Meloto, C.B.; Smith, S.; et al. Painful Temporomandibular Disorder: Decade of Discovery from OPPERA Studies. J. Dent. Res. 2016, 95, 1084–1092. [CrossRef]

10. Lee, J.Y.; Kim, S.W.; Bae, K.Y.; Kim, J.M.; Shin, I.S.; Yoon, J.S. Factors associated with posttraumatic stress disorder symptoms among community volunteers during the Sewol ferry disaster in Korea. Compr. Psychiatry 2017, 77, 38–44. [CrossRef]

11. Bienvenu, O.J.; Colantuoni, E.; Mendez-Tellez, P.A.; Shanholtz, C.; Dennison-Himmelfarb, C.R.; Pronovost, P.J.; Needham, D.M. Cooccurrence of depression and post-traumatic stress disorder: A 2-year longitudinal study. Crit. Care Med. 2015, 43, 642–653. [CrossRef]

12. McFarlane, A.C. Posttraumatic stress disorder of the longitudinal course and the role of risk factors. J. Clin. Psychiatry 2000, 61, 15–20.

13. Song, J.Y.; Jeong, K.S.; Choi, K.S.; Kim, M.G.; Ahn, Y.S. Psychological Risk Factors for Posttraumatic Stress Disorder in Workers After Toxic Chemical Spill in Gumi, South Korea. Workplace Health Saf. 2018, 66, 393–402. [CrossRef]

14. Budimir, S.; Probst, T.; Pieh, C. Coping strategies and mental health during COVID-19 lockdown. J. Ment. Health 2021, 30, 156–163. [CrossRef]

15. Chen, H.; Zhao, X.; Zeng, M.; Li, J.; Ren, X.; Zhang, M.; Liu, Y.; Yang, J. Collective self-esteem and perceived stress among the non-infected general public in China during the 2019 coronavirus pandemic: A multiple mediation model. Pers. Individ. Dif. 2021, 168, 110308. [CrossRef]

16. Invitto, S.; Romano, D.; Garbarini, F.; Bruno, V.; Urgesi, C.; Curcio, G.; Grasso, A.; Pellicciari, M.C.; Kock, G.; Betti, V.; et al. Major Stress-Related Symptoms During the Lockdown: A Study by the Italian Society of Psychophysiology and Cognitive Neuroscience. Front. Public Health 2021, 9, 636089. [CrossRef]

17. Saita, E.; Facchin, F.; Pagnini, F.; Molgora, S. In the Eye of the COVID-19 Storm: A Web-Based Survey of Psychological Distress Among People Living in Lombardy. Front. Psychol. 2021, 12, 566753. [CrossRef]

18. Havnen, A.; Anyan, F.; Hjemdal, O.; Solem, S.; Gurigard Riksfjord, M.; Hagen, K. Resilience Moderates Negative Outcome from Stress during the COVID-19 Pandemic: A Moderated-Mediation Approach. Int. J. Environ. Res. Public Health 2020, 17, 6461. [CrossRef]

19. Li, X.; Lyu, H. Epidemic Risk Perception, Perceived Stress, and Mental Health During COVID-19 Pandemic: A Moderated Mediating Model. Front. Psychol. 2020, 11, 563741. [CrossRef]

20. Manning, K.; Zvolensky, M.J.; Garey, L.; Long, L.J.; Gallagher, M.W. The explanatory role of fatigue severity in the relation between COVID-19 perceived stress and depression, anxiety, and panic severity. Cogn. Behav. Ther. 2021, 51, 89–99. [CrossRef]

21. Swami, V.; Horne, G.; Furnham, A. COVID-19-related stress and anxiety are associated with negative body image in adults from the United Kingdom. Pers. Individ. Dif. 2021, 170, 110426. [CrossRef] [PubMed]

22. Szabo, C.; Pukanszky, J.; Kemeny, L. Psychological Effects of the COVID-19 Pandemic on Hungarian Adults. Int. J. Environ. Res. Public Health 2020, 17, 9565. [CrossRef] [PubMed]

23. Varma, P.; Junge, M.; Meaklim, H.; Jackson, M.L. Younger people are more vulnerable to stress, anxiety and depression during COVID-19 pandemic: A global cross-sectional survey. Prog. Neuropsychopharmacol. Biol. Psychiatry 2021, 109, 110236. [CrossRef] [PubMed]

24. Barbato, M.; Thomas, J. In this together: Psychological wellbeing of foreign workers in the United Arab Emirates during the COVID-19 pandemic. Int. J. Psychol. 2021, 56, 825–833. [CrossRef]

25. Lu, R.; Pu, W.; Dai, L.; Yang, R.; Wang, P. Comparison of Psychological Stress Levels and Associated Factors Among Healthcare Workers, Frontline Workers, and the General Public During the Novel Coronavirus Pandemic. Front. Psychiatry 2020, 11, 583971. [CrossRef] [PubMed]

26. Megalakaki, O.; Kokou-Kpolou, C.K.; Vaude, J.; Park, S.; Iorfia, S.K.; Cenat, J.M.; Dériois, D. Does peritraumatic distress predict PTSD, depression and anxiety symptoms during and after COVID-19 lockdown in France? A prospective longitudinal study. J. Psychiatr. Res. 2021, 137, 81–88. [CrossRef]
27. Gori, A.; Topino, E. Across the COVID-19 Waves; Assessing Temporal Fluctuations in Perceived Stress, Post-Traumatic Symptoms, Worry, Anxiety and Civic Moral Disengagement over One Year of Pandemic. Int. J. Environ. Res. Public Health 2021, 18, 5651. [CrossRef]

28. Huang, Y.; Wang, Y.; Zeng, L.; Yang, J.; Song, X.; Rao, W.; Li, H.; Ning, Y.; He, H.; Li, T.; et al. Prevalence and Correlation of Anxiety, Insomnia and Somatic Symptoms in a Chinese Population During the COVID-19 Epidemic. Front. Psychiatry 2020, 11, 568329. [CrossRef]

29. Dillard, A.J.; Meier, B.P. Trait mindfulness is negatively associated with distress related to COVID-19. Pers. Individ. Dif. 2021, 179, 110955. [CrossRef]

30. Janson, M.; Sharkey, J.D.; Del Cid, D.A. Predictors of Mental Health Outcomes in Grocery Store Workers amid the COVID-19 Pandemic and Implications for Workplace Safety and Moral Injury. Int. J. Environ. Res. Public Health 2022, 19, 8675. [CrossRef]

31. Midorikawa, H.; Aiba, M.; Lebowitz, A.; Taguchi, T.; Shiratori, Y.; Ogawa, T.; Takahashi, A.; Takahashi, S.; Nemoto, K.; Arai, T.; et al. Confirming validity of the Fear of COVID-19 Scale in Japanese with a nationwide large-scale sample. PLoS ONE 2021, 16, e0246840. [CrossRef]

32. Kira, I.A.; Shuwiekh, H.A.M.; Ashby, J.S.; Elwakeel, S.A.; Alhuwailah, A.; Sous, M.S.F.; Baali, S.B.A.; Azdaou, C.; Oliemat, E.M.; Jamil, H.J. The Impact of COVID-19 Traumatic Stressors on Mental Health: Is COVID-19 a New Trauma Type. Int. J. Ment. Health Addict. 2021, 1–20. [CrossRef]

33. Spitzer, R.L.; Kroenke, K.; Williams, J.B.; Lowe, B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch. Intern. Med. 2006, 166, 1092–1097. [CrossRef] [PubMed]

34. Reiss, S.; Peterson, R.A.; Gorsky, D.M.; McNally, R.J. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav. Res. Ther. 1986, 24, 1–8. [CrossRef]

35. Weiss, D.S. The Impact of Event Scale: Revised. In Cross-Cultural Assessment of Psychological Trauma and PTSD; Springer Science + Business Media: New York, NY, USA, 2007; pp. 219–238.

36. Hosey, M.M.; Leoutsakos, J.S.; Li, X.; Dinglas, V.D.; Bienvenu, O.J.; Parker, A.M.; Hopkins, R.O.; Needham, D.M.; Neufeld, K.J. Screening for posttraumatic stress disorder in ARDS survivors: Validation of the Impact of Event Scale-6 (IES-6). Crit. Care 2019, 23, 276. [CrossRef]

37. Pennebaker, J.W. The Psychology of Physical Symptoms; Springer Publishing: New York, NY, USA, 1982; pp. i–x, 1–197.

38. Gierz, B.; Kohlmann, S.; Kroenke, K.; Spangenberg, L.; Zenger, M.; Brahler, E.; Lowe, B. The somatic symptom scale-8 (SSS-8): A brief measure of somatic symptom burden. JAMA Intern. Med. 2014, 174, 399–407. [CrossRef]

39. Toussaint, A.; Murray, A.M.; Voigt, K.; Herzog, A.; Gierk, B.; Kroenke, K.; Rief, W.; Henningsen, P.; Lowe, B. Development and Validation of the Somatic Symptom Disorder-B Criteria Scale (SSD-12). Psychosom. Med. 2016, 78, 5–12. [CrossRef]

40. Kroenke, K.; Spitzer, R.L.; Williams, J.B. The PHQ-9: Validity of a brief depression severity measure. J. Gen. Intern. Med. 2001, 16, 606–613. [CrossRef]

41. Goldberg, L.R. The development of markers for the Big-Five factor structure. Psychol. Assess. 1992, 4, 26–42. [CrossRef]

42. Cohen, S.; Kamarck, T.; Mermelstein, R. A global measure of perceived stress. J. Health Soc. Behav. 1983, 24, 385–396. [CrossRef]

43. Ware, J.E., Jr.; Sherbourne, C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992, 30, 473–483. [CrossRef] [PubMed]

44. Ruscheveth, R.; Marzinik, M.; Stumpenhorst, F.; Reinholz, J.; Knecht, S. Pain sensitivity can be assessed by self-rating: Development and validation of the Pain Sensitivity Questionnaire. Pain 2009, 146, 65–74. [CrossRef]

45. Buyse, D.J.; Reynolds, C.F., 3rd; Monk, T.H.; Berman, S.R.; Kupfer, D.J. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28, 193–213. [CrossRef]

46. Amerio, A.; Lugo, A.; Stival, C.; Fanucchi, T.; Gorini, G.; Pacifici, R.; Odone, A.; Serafini, G.; Gallus, S. COVID-19 lockdown impact on mental health in a large representative sample of Italian adults. J. Affect. Disord. 2021, 292, 398–404. [CrossRef]

47. Bauerle, A.; Steinbach, J.; Schweda, A.; Beckord, J.; Hetkamp, M.; Weismuller, B.; Kohler, H.; Musche, V.; Dorrie, N.; Teufel, M.; et al. Mental Health Burden of the COVID-19 Outbreak in Germany: Predictors of Mental Health Impairment. J. Prim. Care Community Health 2020, 11, 2150132720953682. [CrossRef]

48. Daly, M.; Robinson, E. Anxiety reported by US adults in 2019 and during the 2020 COVID-19 pandemic: Population-based evidence from two nationally representative samples. J. Affect. Disord. 2021, 286, 296–300. [CrossRef]

49. Hampshire, A.; Hellyer, P.J.; Soreq, E.; Mehta, M.A.; Ioannidis, K.; Trender, W.; Grant, J.E.; Chamberlain, S.R. Associations between dimensions of behaviour, personality traits, and mental-health during the COVID-19 pandemic in the United Kingdom. Nat. Commun. 2021, 12, 4111. [CrossRef]

50. Robillard, R.; Saad, M.; Edwards, J.; Solomonova, E.; Pennestri, M.H.; Daros, A.; Veissiere, S.P.L.; Quilty, L.; Dion, K.; Nixon, A.; et al. Social, financial and psychological stress during an emerging pandemic: Observations from a population survey in the acute phase of COVID-19. BMJ Open 2020, 10, e043805. [CrossRef]

51. Zhao, X.; Lan, M.; Li, H.; Yang, J. Perceived stress and sleep quality among the non-diseased general public in China during the 2019 coronavirus disease: A moderated mediation model. Sleep Med. 2021, 77, 339–345. [CrossRef]

52. Baker, D.G.; Mendenhall, C.L.; Simbartl, L.A.; Magan, L.K.; Steinberg, J.L. Relationship between posttraumatic stress disorder and self-reported physical symptoms in Persian Gulf War veterans. Arch. Intern. Med. 1997, 157, 2076–2078. [CrossRef]

53. Solomon, Z.; Mikulincer, M. Combat stress reactions, post traumatic stress disorder and somatic complaints among Israeli soldiers. J. Psychosom. Res. 1987, 31, 131–137. [CrossRef]
54. Solomon, Z.; Mikulincer, M.; Habershaim, N. Life-events, coping strategies, social resources, and somatic complaints among combat stress reaction casualties. Br. J. Med. Psychol. 1990, 63, 137–148. [CrossRef] [PubMed]

55. McFarlane Ao, A.C.; Graham, D.K. The ambivalence about accepting the prevalence somatic symptoms in PTSD: Is PTSD a somatic disorder? J. Psychiatr. Res. 2021, 143, 388–394. [CrossRef]

56. Astill Wright, L.; Roberts, N.P.; Lewis, C.; Simon, N.; Hyland, P.; Ho, G.W.K.; McElroy, E.; Bisson, J.I. High prevalence of somatization in ICD-11 complex PTSD: A cross sectional cohort study. J. Psychosom. Res. 2021, 148, 110574. [CrossRef]

57. Ginzburg, K.; Solomon, Z. Trajectories of stress reactions and somatization symptoms among war veterans: A 20-year longitudinal study. Psychol. Med. 2011, 41, 353–362. [CrossRef]

58. Ottisova, L.; Gillard, J.A.; Wood, M.; Langford, S.; John-Baptiste Bastien, R.; Madinah Haris, A.; Wild, J.; Bloomfield, M.A.P.; et al. Increases in posttraumatic stress disorder (PTSD) and There Is Consistent Evidence That Chronic Pain Is Associated with PTSD: An Evidence-Based Structured Systematic Review. Pain Med. 2013, 711–735. [CrossRef] [PubMed]

59. Fishbain, D.A.; Vulcano, V.; Lewis, J.E.; Gao, J. Chronic Pain Types Differ in Their Reported Prevalence of Post-Traumatic Stress Disorder (PTSD) and There Is Consistent Evidence That Chronic Pain Is Associated with PTSD: An Evidence-Based Structured Systematic Review. Pain Med. 2017, 17, 697–707. [CrossRef] [PubMed]

60. Astill Wright, L.; Roberts, N.P.; Lewis, C.; Simon, N.; Hyland, P.; Ho, G.W.K.; McElroy, E.; Bisson, J.I. High prevalence of somatization in ICD-11 complex PTSD: A cross sectional cohort study. J. Psychosom. Res. 2021, 148, 110574. [CrossRef]

61. Fraile Pinto, A.L.C.; Serpa, A.L.O.; de Paula, J.J.; Costa, D.S.; Robis, K.; Diaz, A.P.; Joaquim, R.M.; de Miranda, D.M.; Malloy-Diniz, L.F. Increased risk of health professionals to feel traumatized during the COVID-19 pandemic. Sci. Rep. 2021, 11, 18286. [CrossRef]

62. Kim, H.J.; Meeker, T.J.; Tulloch, I.K.; Salazar, P.L.; Solar, A.; Carey, L.; Fogle, B.M.; Schmidt, N.B.; Zvolensky, M.J. COVID-19 and Anxiety Sensitivity Across Two Studies in Argentina: Associations with COVID-19 Worry, Symptom Severity, Anxiety, and Functional Impairment. Cognit. Ther. Res. 2021, 45, 697–707. [CrossRef] [PubMed]

63. Rogers, A.H.; Bogiaizian, D.; Salazar, P.L.; Solari, A.; Carey, L.; Fogle, B.M.; Schmidt, N.B.; Zvolensky, M.J. COVID-19 and Anxiety Sensitivity Moderates the Impact of COVID-19 Perceived Stress on Anxiety and Functional Impairment. Cognit. Ther. Res. 2021, 45, 689–696. [CrossRef]

64. Conti, C.; Fontanesi, L.; Lanzara, R.; Rosa, I.; Porcelli, P. Fragile heroes. The psychological impact of the COVID-19 pandemic on health-care workers in Italy. PLoS ONE 2020, 15, e0242538. [CrossRef]

65. Braule Pinto, A.L.C.; Serpa, A.L.O.; de Paula, J.J.; Costa, D.S.; Robis, K.; Diaz, A.P.; Joaquim, R.M.; de Miranda, D.M.; Malloy-Diniz, L.F. Increased risk of health professionals to feel traumatized during the COVID-19 pandemic. Sci. Rep. 2021, 11, 18286. [CrossRef]

66. Kim, H.J.; Meeker, T.J.; Tulloch, I.K.; Mullins, J.; Park, J.-H.; Bae, S.H. Pandemic Fatigue and Anxiety Sensitivity as Associated Factors With Posttraumatic Stress Symptoms Among University Students in South Korea During the Prolonged COVID-19 Pandemic. Int. J. Public Health 2022, 67, 1604552. [CrossRef]

67. Rogers, A.H.; Bogiaizian, D.; Salazar, P.L.; Solar, A.; Carey, L.; Fogle, B.M.; Schmidt, N.B.; Zvolensky, M.J. COVID-19 and Anxiety Sensitivity Across Two Studies in Argentina: Associations with COVID-19 Worry, Symptom Severity, Anxiety, and Functional Impairment. Cognit. Ther. Res. 2021, 45, 697–707. [CrossRef] [PubMed]

68. Fillingim, R.B.; Ohrbach, R.; Greenspan, J.D.; Knott, C.; Diatchenko, L.; Dubner, R.; Bair, E.; Bariaan, C.; Mack, N.; Slade, G.D.; et al. Psychological factors associated with development of TMD: The OPPERA prospective cohort study. J. Pain 2013, 14, 775–790. [CrossRef]

69. Ottisova, L.; Gillard, J.A.; Wood, M.; Langford, S.; John-Baptiste Bastien, R.; Madinah Haris, A.; Wild, J.; Bloomfield, M.A.P.; Robertson, M. Effectiveness of psychosocial interventions in mitigating adverse mental health outcomes among disaster-exposed health care workers: A systematic review. J. Trauma Stress 2022, 35, 746–758. [CrossRef]

70. Movahed, M.; Khaleghi-Nekou, M.; Alvaní, E.; Sharif-Alhoseini, M. The Impact of Psychological First aid Training on the Impact of COVID-19 Among Spanish Healthcare Workers. A Large Longitudinal Survey. Epidemiol. Psychiatr. Sci. 2022, 31, e28. [CrossRef]

71. Solomon, Z.; Mikulincer, M.; Habershaim, N. Life-events, coping strategies, social resources, and somatic complaints among combat stress reaction casualties. Br. J. Med. Psychol. 1990, 63, 137–148. [CrossRef] [PubMed]

72. Benatov, J.; Ochnik, D.; Rogowska, A.M.; Arzenšek, A.; Mars Bitenc, U. The ambivalence about accepting the prevalence somatic symptoms in PTSD: Is PTSD a somatic disorder? J. Psychiatr. Res. 2021, 143, 388–394. [CrossRef]

73. Astill Wright, L.; Roberts, N.P.; Lewis, C.; Simon, N.; Hyland, P.; Ho, G.W.K.; McElroy, E.; Bisson, J.I. High prevalence of somatization in ICD-11 complex PTSD: A cross sectional cohort study. J. Psychosom. Res. 2021, 148, 110574. [CrossRef]

74. Kowal, M.; Serafim, S.D.; Colombo, R.; Hogg, B.; Calderarero, M.A.; Rosa, A.R. COVID-19 and mental health in Brazil: Psychiatric symptoms in the general population. J. Psychiatr. Sci. 2022, 31, 2019–2024. [CrossRef] [PubMed]

75. Ginzburg, K.; Solomon, Z. Trajectories of stress reactions and somatization symptoms among war veterans: A 20-year longitudinal study. Psychol. Med. 2011, 41, 353–362. [CrossRef]
76. Turna, J.; Zhang, J.; Lamberti, N.; Patterson, B.; Simpson, W.; Francisco, A.P.; Bergmann, C.G.; Ameringen, M.V. Anxiety, depression and stress during the COVID-19 pandemic: Results from a cross-sectional survey. *J. Psychiatr. Res.* 2021, 137, 96–103. [CrossRef]

77. Lawal, A.M. Toward understanding the mental health of nigerian residents during lockdown: The influence of age and vulnerability to COVID-19. *J. Ment. Health* 2021, 30, 202–207. [CrossRef]

78. Cunningham, T.J.; Fields, E.C.; Garcia, S.M.; Kensinger, E.A. The relation between age and experienced stress, worry, affect, and depression during the spring 2020 phase of the COVID-19 pandemic in the United States. *Emotion* 2021, 21, 1660–1670. [CrossRef]